Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 46 to 60 of 136 results for sclerosis

  1. Dronabinol for treating muscle spasticity in multiple sclerosis after 2 treatments [TSID10638]

    Topic prioritisation

  2. Ocrelizumab for treating relapsing–remitting multiple sclerosis in people 10 to 17 years [TSID12164]

    Topic prioritisation

  3. Gastroparesis in adults: oral erythromycin (ESUOM13)

    Summary of the evidence on oral erythromycin for gastroparesis (delayed stomach emptying) in adults to inform local NHS planning and decision-making

  4. Dimethyl fumarate for treating relapsing-remitting multiple sclerosis in people aged 13 to 17 [TSID11778]

    Topic prioritisation

  5. Percutaneous laser therapy for fetal tumours (HTG118)

    Evidence-based recommendations on percutaneous laser therapy for fetal tumours. This involves inserting a needle through the mother's abdomen to the tumour and using laser energy to shrink it.

  6. Sodium phenylbutyrate–ursodoxicoltaurine for treating amyotrophic lateral sclerosis [ID6246]

    Discontinued Reference number: GID-TA11264

  7. Renal replacement therapy and conservative management (NG107)

    This guideline covers renal replacement therapy (dialysis and transplantation) and conservative management for people with chronic kidney disease stages 4 and 5. It aims to improve quality of life by making recommendations on planning, starting and switching treatments, and coordinating care.

  8. Urinary incontinence in neurological disease: assessment and management (CG148)

    This guideline covers assessing and managing urinary incontinence in children, young people and adults with neurological disease. It aims to improve care by recommending specific treatments based on what symptoms and neurological conditions people have.

  9. Ganaxolone for treating seizures caused by CDKL5 deficiency disorder in people 2 years and over (TA1033)

    Evidence-based recommendations on ganaxolone (Ztalmy) for treating seizures caused by CDKL5 deficiency disorder in people 2 years and over.

  10. Infantile spasms: Does treatment response relate to cause in infantile spasms? Does early treatment success in seizure control and resolution of the hypsarrhythmic EEG influence the long-term developmental and cognitive outcomes more than the underlying cause of the spasms?

    steroids over vigabatrin, although this excluded children with tuberous sclerosis. This study provided no specific subgroup analysis...

  11. icobrain ms for active relapsing–remitting multiple sclerosis (MIB291)

    NICE has developed a medtech innovation briefing (MIB) on icobrain ms for active relapsing–remitting multiple sclerosis .

  12. Natalizumab (originator and biosimilar) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy (TA1126)

    Evidence-based recommendations on natalizumab originator (Tysabri) and biosimilar (Tyruko) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy in adults.

  13. The Vest for delivering high-frequency chest wall oscillation in people with complex neurological needs (MIB159)

    NICE has developed a medtech innovation briefing (MIB) on The Vest for delivering high-frequency chest wall oscillation in people with complex neurological needs .

  14. Epilepsies in children, young people and adults (NG217)

    This guideline covers diagnosing and managing epilepsy in children, young people and adults in primary and secondary care, and referral to tertiary services. It aims to improve diagnosis and treatment for different seizure types and epilepsy syndromes, and reduce the risks for people with epilepsy.

  15. Stereotactic radiosurgery for trigeminal neuralgia (HTG608)

    Evidence-based recommendations on stereotactic radiosurgery for trigeminal neuralgia in adults. This involves focusing radiation on the trigeminal nerve to damage it, thereby relieving pain.